ANS Biotech is pleased to announce a significant achievement in our collaboration with a prominent pharmaceutical company based in Barcelona, Spain. This case study highlights the efficacy and precision of our ALGOGram™ technology in advancing our client’s drug development process.
Utilizing ALGOGram™ for Compound Ranking
ANS Biotech successfully partnered with a Spanish pharmaceutical company to rank 26 compounds from various chemical series using our innovative ALGOGram™ technology. Our comprehensive screening process enabled the identification of a standout compound showing a signal in neuropathic pain which was subsequently confirmed in fully powered studies.
This crucial finding has propelled the compound into Phase II clinical trials for Chemotherapy-Induced Peripheral Neuropathy (CIPN).
Critical Role of ALGOGram™ in Drug Development
This case study underscores the critical role of ALGOGram™ in precise compound ranking, enabling informed GO/NO-GO decisions, and streamlining the drug development pipeline for enhanced outcomes. By leveraging ALGOGram™, our client could make strategic decisions with confidence, significantly de-risking the development process and enhancing the potential for clinical success.
Maximizing R&D Success with ALGOGram™
ALGOGram™ is your key to accelerating research and development and maximizing the success of your drug pipeline. This robust in vivo screening tool delivers a comprehensive pharmacological profile across five critical pain areas, using 10 validated pain models. Fast-track your decision-making process with our unique analgesic fingerprint, which not only pinpoints efficacy but also assesses behavioral toxicity.
Proven Success with ALGOGram™
With almost 400 compounds successfully profiled and results available in just three weeks, ALGOGram™ stands out as a reliable and rapid solution for enhancing R&D outcomes. Our technology has consistently demonstrated its capability to deliver rapid, reliable results, driving innovation and success in pain management research.
